Changwon Wang

Changwon Wang

Auto-generated profile, based on publicly available information

Changwon Wang

Biomedical Engineering Research Center, Asan Medical Center, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2023 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
CWChangwon Wang
Changwon Wang
CLChungkeun Lee
Chungkeun Lee
Hangsik ShinHangsik Shin
Hangsik Shin
As a new therapeutic technique based on digital technology, the commercialization and clinical application of digital therapeutics (DTx) are increasing, and the demand for expansion to new clinical fields is remarkably high. However, the use of DTx as a general medical component is still ambiguous, and this ambiguity may be owing to a lack of consensus on a definition, in addition to insufficiencies in research and development, clinical trials, standardization of regulatory frameworks, and technological maturity. In this study, we conduct an in-depth investigation and analysis of definitions, clinical trials, commercial products, and the regulatory status related to DTx using published literature, ClinicalTrials.gov, and web pages of regulatory and private organizations in several countries. Subsequently, we suggest the necessity and considerations for international agreements on the definition and characteristics of DTx, focusing on the commercialization characteristics. In addition, we discuss the status and considerations of clinical research, key technology factors, and the direction of regulatory developments. In conclusion, for the successful settlement of DTx, real-world evidence-based validation should be strengthened by establishing a cooperative system between researchers, manufacturers, and governments, and there should be effective technologies and regulatory systems for overcoming engagement barriers of DTx.

13 May 2024 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
JPJi Hyeun Park
Ji Hyeun Park
CWChangwon Wang
Changwon Wang
Hangsik ShinHangsik Shin
Hangsik Shin
The demand for home sleep apnea testing (HSAT) devices is escalating, particularly in the context of the coronavirus 2019 (COVID-19) pandemic. The absence of standardized development and verification procedures poses a significant challenge. This study meticulously analyzed the approval process characteristics of HSAT devices by the U.S. Food and Drug Administration (FDA) from September 1, 2003, to September 1, 2023, with a primary focus on ensuring safety and clinical effectiveness. We examined 58 reports out of 1046 that underwent FDA clearance via the 510(k) and de novo pathways. A substantial surge in certifications after the 2022 pandemic was observed. Type-3 devices dominated, signifying a growing trend for both home and clinical use. Key measurement items included respiration and sleep analysis, with the apnea–hypopnea index (AHI) and sleep stage emerging as pivotal indicators. The majority of FDA-cleared HSAT devices adhered to electrical safety and biocompatibility standards. Critical considerations encompass performance and function testing, usability, and cybersecurity. This study emphasized the nearly indispensable role of clinical trials in ensuring the clinical effectiveness of HSAT devices. Future studies should propose guidances that specify stringent requirements, robust clinical trial designs, and comprehensive performance criteria to guarantee the minimum safety and clinical effectiveness of HSATs.

1 May 2020 in Smart Health
Verified
Journal Article
Closed access
DKDae Gyeom Kim
Dae Gyeom Kim
CWChangwon Wang
Changwon Wang
JHJong Gab Ho
Jong Gab Ho
Se Dong MinSe Dong Min
Se Dong Min
Young KimYoung Kim
Young Kim
MCMin Hyung Choi
Min Hyung Choi